Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.59)
# 820
Out of 4,937 analysts
84
Total ratings
54.41%
Success rate
23.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintains: In-Line | $3 → $2 | $2.65 | -24.39% | 5 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $55.00 | +80.00% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $16.94 | +165.64% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $8.31 | +44.40% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.21 | +126.24% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.27 | +159.26% | 2 | Dec 11, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $32.15 | +8.86% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $345.73 | +4.13% | 9 | Aug 8, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $438 → $515 | $366.54 | +40.50% | 18 | Aug 2, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $438.93 | -40.77% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.08 | +85.19% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $9.17 | +260.07% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $50.46 | -24.69% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $27.54 | +190.49% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $6.26 | +187.77% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $3.45 | +624.64% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $6.92 | +795.95% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $6.82 | +413.57% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $19.78 | +21.33% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $11.45 | +162.12% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.40 | +194.12% | 1 | Feb 5, 2020 |
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $2.65
Upside: -24.39%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $55.00
Upside: +80.00%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $16.94
Upside: +165.64%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $8.31
Upside: +44.40%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.21
Upside: +126.24%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.27
Upside: +159.26%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $32.15
Upside: +8.86%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $345.73
Upside: +4.13%
Vertex Pharmaceuticals
Aug 2, 2024
Maintains: Outperform
Price Target: $438 → $515
Current: $366.54
Upside: +40.50%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $438.93
Upside: -40.77%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.08
Upside: +85.19%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $9.17
Upside: +260.07%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $50.46
Upside: -24.69%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $27.54
Upside: +190.49%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $6.26
Upside: +187.77%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $3.45
Upside: +624.64%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $6.92
Upside: +795.95%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $6.82
Upside: +413.57%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $19.78
Upside: +21.33%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $11.45
Upside: +162.12%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.40
Upside: +194.12%